Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

December 01, 2015 10:27 PM ET


Company Overview of Mesoblast Limited

Executive Profile

Jonathan Richard Symonds CBE, BA, FCA

Head of Corporate Finance & Strategy, Mesoblast Limited
AgeTotal Calculated CompensationThis person is connected to 5 Board Members in 5 different organizations across 12 different industries.

See Board Relationships


Mr. Jonathan Richard Symonds, also known as Jon, CBE, BA, FCA, serves as Head of Corporate Finance & Strategy at Mesoblast Limited. Mr. Symonds serves as Senior Advisor at GHO Capital Partners LLP. Mr. Symonds serves as the Chief Financial Officer at Novartis Institutes for BioMedical Research, Inc. since September 1, 2009. Mr. Symonds serves as Deputy Chief Financial Officer at Novartis Vaccines and Diagnostics, Inc. Mr. Symonds joined Mesoblast as an advisor in 2014. ...

Corporate Headquarters

55 Collins Street
Melbourne, Victoria 3000


Phone: 61 3 9639 6036
Fax: 61 3 9639 6030

Board Members Memberships

Independent Non-Executive Director, Chairman of Group Audit Committee and Member of Conduct & Values Committee
Chairman and Chairman of Chairman's Nominations & Remuneration Committee


BA 1980
University of Hertfordshire

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.Chief Executive Officer and Director
Caladrius Biosciences, Inc.
Lode Debrabandere Ph.D., MBAChief Executive Officer, President and Director
Osiris Therapeutics, Inc.
Zami Aberman Executive Chairman and Chief Executive Officer
Pluristem Therapeutics, Inc.
Christian Homsy M.D., MBAChief Executive Officer and Executive Director
Celyad SA
Compensation as of Fiscal Year --.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Mesoblast Limited, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at